[Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].

The multi-center non-randomized clinical study included 38 patients, aged 31-70, with morphologically (histologically and/or cytologically) verified diagnosis of disseminated cutaneous melanoma established objective response in 18.5% and clinically significant effect (55.5%) following first-line treatment with fotemustine in conjunction with cisplatin and tamoxifen. Fotemustine as a first-line component of combination chemotherapy retarded metastatic spread to the brain. Since side-effects incidence was not high, the regimen may be used under outpatient hospital conditions.

[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma]. / Khimioimmunoterapiia dakarbazinom i aranozoi s interferonom-al'fa disseminirovannoi melanomy kozhi (DMK).

Aranoza and dacarbazine (DTIC) monotherapy and in combinations with aranoza and interferon-alpha (IPHN-alpha) as well as DTIC and IPHN-alpha was given to 175 patients (89 males and 86 females, aged 23-78) with disseminated skin melanoma. The effectiveness of aranoza and DTIC monotherapy was practically identical. Total response to DTIC used in combination with IPHN-alpha increased insignificantly: 25.6%--in combination vs. 19.5% DTIC alone (p > 0.05). IPHN-alpha was most effective when used with aranoza (total objective response--31.7% vs. aranoza alone--16%). The best results were reported in cases heretofore untreated with cytostatic drugs. Total response (complete or partial remission) was recorded in 63% vs. 4.5% (p < 0.05) of patients who had received chemotherapy. In cases of aranoza+ IPHN-alpha treatment, complete and partial remission was reported in metastasis of the skin, subcutaneous fat, peripheral, retroperitoneal and abdominal (mesenteric) lymph nodes and lungs. There was no relapse of metastasis of the liver, intestinal tract, bones, breast or ovary.

[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma]. / Khimioterapiia v sochetanii s lazernoi koaguliatsiei ili interstitsial'noi gipertermiei kak metod éffektivnogo kombinirovannogo lecheniia disseminirovannoi melanomy kozhi.

Thirty-eight patients with disseminated skin melanoma received chemotherapy in conjunction with laser coagulation or interstitial hyperthermia of intra- or subcutaneous metastases. Use of combination therapy was followed by a rise to 37% in total response and 16%--complete regression, respectively. Most effectiveness was attained when the dacarbazine + cisplatin + BCNU + tamoxifen regime was employed. In this group of 16 patients (46%), total response was 56% and, what is most significant, 31% in complete regression. In all cases of apparent response, polychemotherapy was administered both before and after laser coagulation or interstitial hyperthermia.

[Clinical evaluation of the efficacy of modern first, second, and third line regimes of chemotherapy in patients with disseminated cutaneous melanoma]. / Klinicheskaia otsenka éffektivnosti sovremennykh rezhimov khimoterapii pervoi, vtoroi i tret'ei linii bol'nykh disseminirovannoi melanomoi kozhi.

The effectiveness and side-effects of various chemotherapy (CT) regimens were compared in 157 patients (74 males and 80 females, aged 23-79) with disseminated skin melanoma (DSM). Most cases had multiple metastases to the skin and subcutaneous fat tissue, regional lymph nodes (59-69%), lung (14-38%) and liver (13-36%); to other sites--82 (52%). Total response in the dacarbazine (DTIC) group was 18% (complete--5, partial--13 and stabilization--29%). DTIC was employed as first-line treatment in 71%. DBDT (cisplatin, DTIC, BCNU, tamoxifen) was used in 42 patients: as first-line--13 (31%), second-line--21 (50%) and third-line (following the first two regimens in cases refractory to treatment or those with response-based evidence of tumor progression)--8 (19%). In DBDT-treated patients, total response was 29% (complete--7, partial 22 and stabilization--38%). Similar results were recorded in the group where 69% were given CT as second- and third-line treatment. The effect of CVD (cisplatin, vinblastin, DTIC) was much the same as that of DTIC alone but was followed by a higher incidence of myelodepression and anemia. Combined treatment with prospidin+ CCNU + BCNU seems to offer more advantage.

[Evaluation of the CCNU-COP regimen for primary refractory and recurrent non-Hodgkin's lymphoma]. / Otsenka éffektivnosti programmy CCNU-COP pri khimioterapii pervichno-rezistentnykh form i retsidivov nekhodzhkinskikh limfom.

Thirty patients with non-Hodgkin's lymphoma with tumor progression after failure of standard anthracyclin and alkylating agent treatment (8), and early-onset relapse after the same therapy received 1-4 cycles of CCNU-COP regimen: (22). Complete and partial regression established in 66.6%: complete--4 (13.3%); partial (regression by more than 50%)--16 (53.3%), and stabilisation of disease--5 (16.7%). Response frequency in patients with low- and moderate-grade tumor was 68%. The most frequent side-effects were leukopenia (60%) and anemia (36.7%) which required special correction in separate cases only. CCNU-COP regimen proved as effective as any other-cost "salvage" ones (ESHAP, MIME, etc.).